Brokerages Set Aktis Oncology (NASDAQ:AKTS) PT at $32.00

Shares of Aktis Oncology (NASDAQ:AKTS) have been given an average rating of “Buy” by the five research firms that are presently covering the stock, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have covered the stock in the last year is $32.00.

A number of brokerages have recently weighed in on AKTS. HC Wainwright raised their target price on Aktis Oncology from $30.00 to $33.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Leerink Partners initiated coverage on shares of Aktis Oncology in a report on Tuesday, February 3rd. They set an “outperform” rating and a $31.00 price objective on the stock. TD Cowen assumed coverage on shares of Aktis Oncology in a research report on Tuesday, February 3rd. They issued a “buy” rating for the company. JPMorgan Chase & Co. assumed coverage on shares of Aktis Oncology in a research note on Tuesday, February 3rd. They issued an “overweight” rating and a $30.00 target price for the company. Finally, Wall Street Zen upgraded shares of Aktis Oncology to a “hold” rating in a research report on Saturday, January 17th.

Key Stories Impacting Aktis Oncology

Here are the key news stories impacting Aktis Oncology this week:

• Positive Sentiment: HC Wainwright sharply reduced its loss forecasts across 2026–2027 (i.e., smaller projected EPS losses), raising quarterly and full‑year estimates — examples: Q1 2026 from ($0.64) to ($0.36), Q2 from ($0.71) to ($0.38), Q3 from ($0.77) to ($0.46), Q4 from ($0.83) to ($0.51), FY2026 from ($2.95) to ($1.72) and FY2027 from ($3.71) to ($2.35). These estimate improvements suggest better-than-expected near‑term performance assumptions and are supportive for the stock. HC Wainwright Forecasts Aktis Oncology Q1 Earnings
• Positive Sentiment: HC Wainwright maintains a “Buy” rating with a $33 price target and headline commentary that AKTS stock is expected to rise — a high‑profile buy rating and substantially higher target provide positive sentiment and potential catalyst for buying interest. Aktis Oncology Stock Price Expected to Rise, HC Wainwright Analyst Says
• Neutral Sentiment: Despite the revisions, consensus and HC Wainwright projections still show the company operating at losses for FY2026 and FY2027 (consensus FY current year EPS ≈ ($0.43)); AKTS remains a developmental-stage/tech oncology name with execution and cash‑burn risk — this tempers upside from analyst optimism. MarketBeat AKTS Profile

Aktis Oncology Price Performance

Shares of AKTS opened at $17.37 on Friday. The company has a fifty day simple moving average of $18.94. Aktis Oncology has a 52-week low of $14.72 and a 52-week high of $29.16.

Insider Activity

In other news, major shareholder Bioventures 2018 L.P. Mpm acquired 1,112,777 shares of the firm’s stock in a transaction on Monday, January 12th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $20,029,986.00. Following the transaction, the insider owned 10,260,064 shares of the company’s stock, valued at approximately $184,681,152. This represents a 12.17% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Helen Susan Kim bought 835,000 shares of the company’s stock in a transaction dated Monday, January 12th. The shares were purchased at an average price of $18.00 per share, with a total value of $15,030,000.00. Following the transaction, the director owned 5,671,825 shares of the company’s stock, valued at $102,092,850. The trade was a 17.26% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have acquired 6,117,776 shares of company stock worth $110,119,968. 3.30% of the stock is owned by company insiders.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.